Name: Pfizer files COVID-19 vaccine application to U.S. FDA
Brand: reuters.com
SKU: reuters-com-2252
Availability: OnlineOnly

critic

Pfizer files COVID-19 vaccine application to U.S. FDA

preview

By Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company’s website on Friday afternoon.The FDA said on Friday it would hold a meeting of the advisory committee on Dec. 10 at which members would discuss the vaccine. The agency declined to predict how long its review would take, although both Pfizer and U.S. Health Secretary Alex Azar have said the FDA could authorize the vaccine in mid-December.Pfizer’s shares closed up 1.4% and BioNTech shares ended 9.6% higher in New York, as the possibility of a vaccine soon raised hopes for the end of a pandemic that has claimed more than a quarter of a million lives in the United States and over 1.3 million worldwide.For an interactive graphic tracking the global spread of COVID-19, open in an external browser.The application also includes safety data on about 100 children 12-15 years of age. The company said 45% of U.S. trial participants are 56-85 years old.If the data is solid, “we literally could be weeks away from the authorization of a 95% effective vaccine,” Azar said on CBS’s “This Morning.”The companies expect the FDA to grant the EUA by mid-December and said they will begin shipping doses almost immediately. Pfizer has said it expects to have 50 million vaccine doses ready this year, enough to protect 25 million people.The final trial data showed the vaccine provided a similar level of protection across different ages and ethnicities - an encouraging result as the disease disproportionately hurts the elderly and minorities.Of the 170 volunteers who contracted COVID-19 in Pfizer’s trial involving over 43,000 people, 162 had received only a placebo, meaning the vaccine was 95% effective, far higher than originally expected. The U.S. FDA had set minimum bar for efficacy of 50%.Pfizer said nearly 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds.“Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine,” Bourla said in a statement.Both the Pfizer/BioNTech and Moderna vaccines work using a new technology to trigger an immune response known as synthetic messenger RNA that can be produced at scale much more quickly than traditional vaccines.Reporting by Vishwadha Chander in Bengaluru, additional reporting by Ankur Banerjee in Bengaluru, Caroline Humer in New York and Doina Chiacu in Washington; Editing by Bill Berkrot and Matthew LewisOur Standards:

By Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company’s website on Friday afternoon.The FDA said on Friday it would hold a meeting of the advisory committee on Dec. 10 at which members would discuss the vaccine. The agency declined to predict how long its review would take, although both Pfizer and U.S. Health Secretary Alex Azar have said the FDA could authorize the vaccine in mid-December.Pfizer’s shares closed up 1.4% and BioNTech shares ended 9.6% higher in New York, as the possibility of a vaccine soon raised hopes for...

public

Vishwadha Chander

Top and breaking news, pictures and videos from Reuters. For more breaking business news, follow @ReutersBiz.

reuters.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Pfizer files COVID-19 vaccine application to U.S. FDA

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS